Details for New Drug Application (NDA): 204311
✉ Email this page to a colleague
NDA 204311 describes ABACAVIR SULFATE AND LAMIVUDINE, which is a drug marketed by Norvium Bioscience, Aurobindo Pharma, Aurobindo Pharma Ltd, Chartwell Rx, Cipla, Laurus, Teva Pharms Usa, and Zydus Pharms, and is included in eight NDAs. It is available from five suppliers. Additional details are available on the ABACAVIR SULFATE AND LAMIVUDINE profile page.
The generic ingredient in ABACAVIR SULFATE AND LAMIVUDINE is abacavir sulfate; lamivudine. There are twelve drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the abacavir sulfate; lamivudine profile page.
The generic ingredient in ABACAVIR SULFATE AND LAMIVUDINE is abacavir sulfate; lamivudine. There are twelve drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the abacavir sulfate; lamivudine profile page.
Summary for 204311
| Tradename: | ABACAVIR SULFATE AND LAMIVUDINE |
| Applicant: | Norvium Bioscience |
| Ingredient: | abacavir sulfate; lamivudine |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, FOR SUSPENSION;ORAL | Strength | EQ 60MG BASE;30MG | ||||
| Approval Date: | Dec 22, 2023 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
